Daniel Asz-Sigall

Daniel Asz-Sigall

Auto-generated profile, based on publicly available information

Daniel Asz-Sigall

Trichology Clinic, Dermatology Department Dr Manuel Gea Gonzalez General Hospital Mexico City Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
NMNekma Meah
Nekma Meah
JLJane Li
Jane Li
DWDmitri Wall
Dmitri Wall
KYKatherine York
Katherine York
BBBevin Bhoyrul
Bevin Bhoyrul
RSRodney Sinclair
Rodney Sinclair
Background: As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objectives: To produce an international consensus statement on the treatment modalities and prognostic indicators of FFA. Methods: Sixty‐nine hair experts from six continents were invited to participate in a three‐round Delphi process. The final stage was held as a virtual meeting facilitated via Zoom. The consensus threshold was set at ≥66%. Results: Of 365 questions, expert consensus was achieved in 204 (56%) questions following completion of the three rounds. Three additional questions were included at the final meeting. The category with the strongest consensus agreement was disease monitoring (9; 100%). Questions pertaining to physical therapies achieved the least category consensus (15; 40%), followed by systemic therapy (45; 43%). Limitations: The study lacked sufficient representation from Africa and South America. Conclusions: SOFFIA highlights areas of agreement and disagreement among experts. Robust research is warranted to provide evidence‐based treatment recommendations.

9 January 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MCMarina Ramos Costa
Marina Ramos Costa
FBFlavia Oliveira de Xavier de Brito
Flavia Oliveira de Xavier de Brito
JYJoão Paulo Yamagata
João Paulo Yamagata
CMCarla Jorge Machado
Carla Jorge Machado
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
DMDaniel Fernandes Melo
Daniel Fernandes Melo

27 February 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
ALAlba Lecumberri
Alba Lecumberri
SVSergio Vano-Galvan
Sergio Vano-Galvan
DADaniel Asz-Sigall
Daniel Asz-Sigall
David Saceda CorraloDavid Saceda Corralo
David Saceda Corralo
Artificial intelligence (AI) is increasingly being incorporated into dermatology, with hair disorders representing a particularly suitable field for its application. The assessment and management of alopecias rely heavily on visual evaluation, pattern recognition, longitudinal monitoring, and integration of heterogeneous clinical and biological data; processes that are often limited by interobserver variability and incomplete standardization. In recent years, AI-based approaches have been applied across multiple domains in the clinical assessment of hair disorders, including objective quantitative assessment, diagnostic support, personalized medicine, drug development, robotic-assisted procedures, and analysis of patient-reported outcomes and clinical communication. Among these applications, tools enabling automated and reproducible measurement of hair parameters are currently the most established in clinical practice, whereas diagnostic and predictive models remain largely investigational. This narrative review summarizes current and emerging applications of artificial intelligence in hair disorders, with a focus on their clinical relevance and practical implementation. In addition, methodological limitations, ethical considerations, and challenges related to external validation, interpretability, and data bias are discussed. Although AI-based tools are not yet able to replace clinical judgement, they hold significant potential to complement dermatologists’ expertise and improve objectivity, efficiency, and personalization in the management of hair disorders.

18 December 2025 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
CMCesar Daniel Villarreal-Villarreal, MD
Cesar Daniel Villarreal-Villarreal, MD
EBE. Boland-Rodriguez
E. Boland-Rodriguez
DMD. Mares-Custodio
D. Mares-Custodio
DAD. Asz-Sigall
D. Asz-Sigall
JGJ.F. Molina-De la Garza
J.F. Molina-De la Garza
SVSergio Vano-Galvan
Sergio Vano-Galvan
Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a novel and very efficient therapy for different types of alopecia. However, information on its safety and efficacy profile in the management of CATE remains scarce. This study aims to evaluate the treatment response to LDOM in CATE patients. We conducted a retrospective study at a single dermatology center. Adult patients diagnosed with telogen effluvium from December 2020 to October 2022, with a prior history of SARS-CoV-2 infection, and treated with LDOM were included. The efficacy of LDOM was evaluated with the hair-shedding score (HSS). In all, 69 patients, 50 (72.5%) women and 19 (27.5%) men were included. A total of 55 patients (79.7%) exhibited mild and moderate symptoms; 8 (11.5%), severe disease; and 6 (8.7%) remained asymptomatic. The time elapsed between COVID-19 and telogen effluvium diagnosis was 117 days (80-181). The HSS continuously decreased during the 2nd, 3rd, and 4th visits after treatment initiation. Compared with baseline, the median (interquartile range) HSS was significantly lower at the 2nd visit (5 [5-6]; P<.001), the 3rd visit (4 [3-5]; P<.001), and the 4th visit (2 [1-2]; P<.001). The time for telogen effluvium resolution was 93 days (55-148). Our findings suggest that LDOM is a safe and effective therapy for patients with CATE.

10 November 2021
Verified
Book Chapter
Closed access
PDF file
SLSergio Enrique Leal-Osuna
Sergio Enrique Leal-Osuna
JGJessica Gonzalez Gutierrez
Jessica Gonzalez Gutierrez
KGKarla Iñigo Gomez
Karla Iñigo Gomez
POPamela Orozco Olguin
Pamela Orozco Olguin
MCMelanie Marmolejo Chavira
Melanie Marmolejo Chavira
DADaniel Asz-Sigall
Daniel Asz-Sigall
Hirsutism is defined as an excessive growth of terminal hair with a male pattern distribution in women. This male pattern distribution is in androgen dependent areas like the chin, upper lip, chest, breast, abdomen, back, and anterior thighs. 1 – 5 It is associated with elevated androgen levels and some patients may present with other secondary conditions such as androgenetic alopecia, acanthosis nigricans, and acne. 2 Hirsutism should be distinguished from hypertrichosis, which is an increased hair growth in a generalized distribution and not limited to androgen dependent areas. 2 , 6 – 9